Interim Report January – September 2022
Third quarter 2022 (July 1 – September 30)• Net sales amounted to SEK 96.8 million (54.9), corresponding to…
Read moreThird quarter 2022 (July 1 – September 30)• Net sales amounted to SEK 96.8 million (54.9), corresponding to…
Read moreXVIVO Perfusion ABs (publ) styrelse meddelar att vd Dag Andersson hastigt gått bort. Styrelsen har fattat beslut om…
Read moreXVIVO Perfusion AB's (publ) board of directors announces that CEO Dag Andersson has suddenly passed away. The board…
Read moreXVIVO Perfusion AB (publ) (“XVIVO” eller ”Bolaget”) har idag tecknat avtal om att förvärva 100 procent av aktierna i Avionord S.r.l:s maskin- och perfusionsverksamhet (“Avionord M&P”), för en köpeskilling om maximalt 12,0 miljoner euro. Initial köpeskilling uppgår till maximalt 9,6 miljoner euro, varav cirka 40 procent av köpeskillingen betalas kontant och 60 procent betalas genom nyemitterade aktier i XVIVO, jämte en potentiell tilläggsköpeskilling om maximalt 2,4 miljoner euro att betalas under 2023. Fullföljandet av förvärvet förväntas ske i november 2022.
Read moreXVIVO Perfusion AB (publ) (“XVIVO” or the “Company”) has today signed an agreement to acquire 100 percent of the shares in Avionord S.r.l.’s machine and perfusion business (“Avionord M&P”) for a purchase price amounting to a maximum of EUR 12.0 million. Initial purchase price amounts to maximum EUR 9.6 million, whereof approximately 40 percent will be paid in cash and 60 per cent by issuance of new shares in XVIVO, with an additional potential earn-out payment of maximum EUR 2.4 million to be paid out in 2023. Completion of the acquisition is expected to take place during November 2022.
Read more